We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » Clavis, Clovis Sign $380 Million Partnership to Develop Anti-Cancer Agent
Clavis, Clovis Sign $380 Million Partnership to Develop Anti-Cancer Agent
November 24, 2009
Clavis Pharma ASA … and Clovis Oncology, Inc., … announced
an agreement for the further development and commercialization of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic
cancer. Earth Times
